Launch week offerEnds in00h00m00s

annual Promonthly Pro

Matthieu Grégoire

France

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in France

Articles (16)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Caroline Monchaud

Université de Limoges

FRANCE

View details

Stephane Corvec

FRANCE

View details

Pascale Bémer

Nantes University Hospital

FRANCE

View details

Eva Benavent

Researcher

Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)

SPAIN

View details

Alex Soriano

Jefe de Servicio

University of Barcelona

SPAIN

View details

Matthieu Million

Aix-Marseille University

FRANCE

View details

Nicolas Venisse

Professeur des Universités - Praticien Hospitalier (PU-PH)

University of Poitiers

FRANCE

View details

François Javaudin

Université de Nantes

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matthieu Grégoire

Research Interests

Make your next move.

Explore related searches

Articles (16)

Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy

Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters

External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV‐Infected Patients

Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study.

A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model

Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections

Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study)

TEMPORARY REMOVAL: Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel

Response to “<scp>CYP450 3A4</scp>/5 Containment During <scp>SARS‐CoV</scp>‐2 Infection”

Impact of Inflammation on Midazolam Metabolism in Severe COVID‐19 Patients

A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment

CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation

Phages versus Antibiotics To Treat Infected Diabetic Wounds in a Mouse Model: a Microbiological and Microbiotic Evaluation

PK/PD targets of amikacin and gentamicin in ICU patients

Development and validation of a dosing nomogram for amoxicillin in infective endocarditis

Potential drug–drug interactions associated with drugs currently proposed for COVID‐19 treatment in patients receiving other treatments

Collaborators (8)

Caroline Monchaud

Stephane Corvec

Pascale Bémer

Eva Benavent

Alex Soriano

Matthieu Million

Nicolas Venisse

François Javaudin

Make your next move.